The Road to a Vaccine
The Road to a Vaccine: What have we learned after eight months of COVID-19?
In Season 2 of The Road to a Vaccine, host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.
In Episode 5 of The Road to a Vaccine, Lisa Ling asks health experts for a pandemic status report, including the latest statistics on cases worldwide, the current thinking about coronavirus and its effects and what’s working to fight the disease—and what’s not.
In Episode 5 of The Road to a Vaccine, Lisa Ling asks health experts for a pandemic status report, including the latest statistics on cases worldwide, the current thinking about coronavirus and its effects and what’s working to fight the disease—and what’s not.
Lisa Ling
Ling is the Executive Producer and host of This Is Life on CNN. She has also been a field correspondent for The Oprah Winfrey Show and a contributor to ABC News’ Nightline.
Jacqueline Phillips, M.D.
Dr. Phillips is a Senior Director in the Child Health Innovation Leadership Department (CHILD) at Johnson & Johnson. She is a board-certified pediatrician and a member of both the American Academy of Pediatrics (AAP) and the Society of Critical Care Medicine (SCCM). Previously, Dr. Phillips was an Associate Professor of Pediatrics at Rutgers Medical School and Medical Director of the Pediatric Intensive Care Unit at the Children’s Hospital.
Paul Stoffels, M.D.
Dr. Stoffels is the Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. He spearheads the research and product pipeline by leading teams across all of the company’s sectors to set the company-wide innovation agenda, discovering and developing transformational healthcare solutions.
5 facts about Johnson & Johnson’s investigational Janssen COVID-19 vaccine candidate
With its global Phase 3 clinical trial now fully enrolled with approximately 45,000 adult participants, we share the most up-to-date information about the single-dose investigational vaccine candidate.
